Thermo Fisher hooks gut onto its gene therapy pipeline, inks new collaboration pact

Seven months ago, Thermo Fisher spent $1.7 billion to add a gene therapy company to its sprawling biotech business, purchasing Brammer Bio. Now they’ve signed a collaboration deal with another, newly well-funded, company from the same founder to expand its gene therapy work into the microbiome.